July 2019
Volume 60, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2019
Adjuvant ursodeoxycholic acid for retinal detachment : a potential neuroprotective therapy.
Author Affiliations & Notes
  • Alejandra Daruich
    Paris Descartes University- U1138, Paris, France
    Hôpital Necker-Enfants Malades, France
  • Emilie Picard
    Paris Descartes University- U1138, Paris, France
  • Marta Zola
    University of Lausanne, Switzerland
  • Hugues Henry
    University of Lausanne, Switzerland
  • Jeffrey H Boatright
    Emory University, Georgia, United States
  • Francine F Behar-Cohen
    Paris Descartes University- U1138, Paris, France
  • Footnotes
    Commercial Relationships   Alejandra Daruich, None; Emilie Picard, None; Marta Zola, None; Hugues Henry, None; Jeffrey Boatright, None; Francine Behar-Cohen, None
  • Footnotes
    Support  Grant Emory University
Investigative Ophthalmology & Visual Science July 2019, Vol.60, 2795. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Alejandra Daruich, Emilie Picard, Marta Zola, Hugues Henry, Jeffrey H Boatright, Francine F Behar-Cohen; Adjuvant ursodeoxycholic acid for retinal detachment : a potential neuroprotective therapy.. Invest. Ophthalmol. Vis. Sci. 2019;60(9):2795. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : 1) To determine whether ursodeoxycholic acid (UA) administered orally and preoperatively to retinal detachment (RD) patients can cross the blood-ocular barrier, and to assess the mean concentration reached in intraocular fluids
2) To determine whether UA is neuroprotective in an ex-vivo rat model of RD at the concentrations found in patients

Methods : 1) Patients presenting with RD for ≥4 days from symptom onset were prospectively included. Twenty-one patients were treated before retinal detachment surgery with UA (10mg/kg) at 4 different intervals (<5 hours, 5-8 hours, 8-11 hours and >11 hours). Five RD patients served as controls. All patients underwent pars-plana vitrectomy. Subretinal fluid and vitreous humor samples were collected during surgery. UA and total protein concentrations were measured in all samples.
2) To evaluate the neuroprotective effect of UA, rat neural retinal explants were cultured in low-serum medium and treated with UA at intraocular concentration ranges ( 10, 50 and 500 ng/ml) found in patients. Markers of apoptosis (caspase 3) and Necrosis (LDH, RIP) were analyzed by western immunoblotting. Immunohistochemistry was performed on sections of fixed retinas (cone arrestin, peanut agglutinin).

Results : 1) UA was found in vitreous and/or subretinal fluid in 12 patients (57%). The concentrations of UA were higher in patients who were treated 8 hours or more before surgery. Controls patients did not present UA in subretinal fluid samples (p=0.04, vs treated patients). The UA concentration in subretinal fluid was correlated with the total protein concentration (p<0.0001).
2) LDH decreased significantly in the medium of treated explants at all doses (10, 50 and 500 ng/ml) from 24 to 48 hours compared to control media (p=0.01, p=0.02, p=0.003, respectively). Caspase 3 was significantly lower in retinas treated at 10 and 50 ng/ml compared to controls (p=0.02). RIP was significantly lower in all treated retinas compared to controls (p=0.02). The number of cones (cone arrestin+) was higher at 50 and 500 ng/ml (P=0.04). The number of cones (Peanut agglutinin +) was higher at 10 ng/ml.

Conclusions : Following oral administartion, UA crosses the blood-ocular barrier in the disrupted state of RD eyes, and accumulates in subretinal fluid at concentrations that confer neuroprotection in an ex-vivo model of RD.

This abstract was presented at the 2019 ARVO Annual Meeting, held in Vancouver, Canada, April 28 - May 2, 2019.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×